Medrol Dosepak for Outpatient Total Knee Arthroplasty
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of an oral methylprednisolone taper on
acute postoperative pain, function, opioid consumption, nausea, and complications following
outpatient total knee arthroplasty (TKA). We hypothesize that administration of an oral
methylprednisolone taper starting on postoperative day 1 (POD 1) following TKA will be
associated with improved pain and decreased opioid use, nausea, and complications at POD1-7,
as compared to similar patients who receive placebo. Additionally, those taking
methylprednisolone will report decreased pain and greater objective functional outcomes at 3
and 6 weeks postoperatively as compared to controls.